BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2020 5:45:32 AM | Browse: 517 | Download: 1231
Publication Name World Journal of Diabetes
Manuscript ID 58245
Country/Territory Russia
Received
2020-07-14 05:14
Peer-Review Started
2020-07-14 05:15
To Make the First Decision
Return for Revision
2020-09-21 18:07
Revised
2020-09-28 11:19
Second Decision
2020-10-13 11:36
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-10-13 17:39
Articles in Press
2020-10-13 17:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
2020-10-26 06:09
Typeset the Manuscript
2020-12-10 07:36
Publish the Manuscript Online
2020-12-13 05:45
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Basic Study
Article Title Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
Manuscript Source Unsolicited Manuscript
All Author List Vadim V Klimontov, Anton I Korbut, Iuliia S Taskaeva, Nataliya P Bgatova, Maksim V Dashkin, Nikolay B Orlov, Anna S Khotskina, Evgenii L Zavyalov and Thomas Klein
ORCID
Author(s) ORCID Number
Vadim V Klimontov http://orcid.org/0000-0002-5407-8722
Anton I Korbut http://orcid.org/0000-0003-3502-5892
Iuliia S Taskaeva http://orcid.org/0000-0002-2812-2574
Nataliya P Bgatova http://orcid.org/0000-0002-4507-093X
Maksim V Dashkin http://orcid.org/0000-0002-5099-5144
Nikolay B Orlov http://orcid.org/0000-0002-9063-4239
Anna S Khotskina http://orcid.org/0000-0001-5379-9977
Evgenii L Zavyalov http://orcid.org/0000-0002-9412-3874
Thomas Klein http://orcid.org/0000-0001-5762-9166
Funding Agency and Grant Number
Funding Agency Grant Number
the Ministry of Education and Science of Russia АААА-А19-119031590017-7/0324-2019-0045-C-02
Boehringer Ingelheim Pharma
Corresponding Author Vadim V Klimontov, DSc, MD, PhD, Professor, Department of Laboratory of Endocrinology, Research Institute of Clinical and Experimental Lymphology–Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL–Branch of IC&G SB RAS), No. 2 Timakov Street, Novosibirsk 630060, Russia. klimontov@mail.ru
Key Words Diabetes; Chronic kidney disease; Albuminuria; Podocyte; Sodium-glucose transporter 2 inhibitors; Empagliflozin
Core Tip In our study, we assessed the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (EMPA) on glomerular structure, with special interest to podocytes, and glomerular staining of nephrin in db/db mice, a model of type 2 diabetic nephropathy. We treated 8-wk-old mice with EMPA (10 mg per kg daily) or vehicle for 8 wks. The results demonstrated that EMPA attenuates podocytopathy and enhances glomerular nephrin staining. These effects were accompanied by mitigation of renal hypertrophy and glomerular transforming growth factor beta expression and decrease in albuminuria. The results contribute to understanding renal protective effect of SGLT2 inhibitors in diabetes.
Publish Date 2020-12-13 05:45
Citation Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World J Diabetes 2020; 11(12): 596-610
URL https://www.wjgnet.com/1948-9358/full/v11/i12/596.htm
DOI https://dx.doi.org/10.4239/wjd.v11.i12.596
Full Article (PDF) WJD-11-596.pdf
Full Article (Word) WJD-11-596.docx
Manuscript File 58245_Auto_Edited-Webster J.docx
Answering Reviewers 58245-Answering reviewers.pdf
Audio Core Tip 58245-Audio core tip.m4a
Biostatistics Review Certificate 58245-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 58245-Conflict-of-interest statement.pdf
Copyright License Agreement 58245-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 58245-Grant application form(s).pdf
Institutional Animal Care and Use Committee Approval Form or Document 58245-Institutional animal care and use committee statement.pdf
Institutional Review Board Approval Form or Document 58245-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 58245-Language certificate.pdf
Peer-review Report 58245-Peer-review(s).pdf
Scientific Misconduct Check 58245-Scientific editor work list.pdf
Scientific Misconduct Check 58245-Bing-Fan JR-2.png
Scientific Misconduct Check 58245-Bing-Zhang L-1.png
Scientific Misconduct Check 58245-Scientific misconduct check.pdf